Braveheart Bio (BRVE) 10% Owner Erez Chimovits Buys $34.92M, Converts Preferred

What Happened
Erez Chimovits (reported as a 10% owner) reported multiple transactions on August 7, 2026 tied to Braveheart Bio’s IPO. He purchased 1,940,000 shares in the offering (1,666,667 + 273,333) at $18.00 each for a total cash outlay of $34,920,000. In addition, Chimovits reported conversions of derivative securities: one conversion resulting in the acquisition of 9,132,420 common shares (see footnote F1) and a separate conversion event reported as a disposition of 40,000,000 shares at $0.00. Footnote F1 explains Series A preferred automatically converted into common stock on a 1-for-4.38 basis upon the IPO close, without payment.

Key Details

• Transaction date: August 7, 2026; Form 4 filed August 11, 2026.
• Purchases: 1,666,667 shares @ $18.00 = $30,000,006 (IPO) and 273,333 shares @ $18.00 = $4,919,994 (IPO). Total cash purchases = $34,920,000. (Footnote F2: these reflect IPO purchases.)
• Conversions: +9,132,420 shares reported acquired via conversion of derivative security (F1). A separate conversion is reported as a disposition of 40,000,000 shares at $0.00 (report lists this as a derivative conversion/disposition).
• Shares owned after transaction: not specified in the provided filing data.
• Notable footnotes: F1 (automatic Series A preferred → common conversion on IPO close); F2 (IPO purchase). Other footnotes in the filing relate to OrbiMed entities and reporting/pecuniary-interest disclaimers (F3–F5).
• Timeliness: Form 4 covers Aug 7 transactions and was filed Aug 11, 2026 (no late-filing flag noted in the provided information).

Context: The cash purchases in the IPO are straightforward acquisitions (often viewed as a stronger signal than routine sales because they involve personal capital). The reported $0.00 “disposition” tied to a derivative conversion likely reflects conversion mechanics associated with preferred-to-common transactions at IPO rather than a cash sale; see footnote F1 for conversion terms. As a 10% owner, Chimovits’s report reflects sizable institutional-level holdings/transactions rather than routine executive trading.